My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 169

    1.

    Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.

    Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM.

    Diabetes Care. 2002 Feb;25(2):376-80.PMID: 11815513 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

    Diabetes. 2002 Oct;51(10):2968-74.PMID: 12351435 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

    Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S.

    Ann Intern Med. 2004 May 18;140(10):786-94.PMID: 15148065 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.

    Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A.

    Endocrine. 2004 Dec;25(3):207-14.PMID: 15758247 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.

    Metabolism. 2007 Oct;56(10):1396-401.PMID: 17884451 [PubMed - indexed for MEDLINE]Related articles

    7.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    8.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    9.

    The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.

    Sidhu JS, Cowan D, Kaski JC.

    J Am Coll Cardiol. 2003 Nov 19;42(10):1757-63.PMID: 14642684 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    11.

    Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.

    Sidhu JS, Cowan D, Tooze JA, Kaski JC.

    Am Heart J. 2004 Jun;147(6):e25.PMID: 15199366 [PubMed - indexed for MEDLINE]Related articles

    12.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    13.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    14.

    Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

    Lebovitz HE, Kreider M, Freed MI.

    Diabetes Care. 2002 May;25(5):815-21.PMID: 11978674 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.

    Dolezalová R, Haluzík MM, Bosanská L, Lacinová Z, Kasalová Z, Stulc T, Haluzík M.

    Physiol Res. 2007;56(6):741-8. Epub 2006 Nov 6.PMID: 17087601 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

    Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

    17.

    Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.

    Osei K, Gaillard T, Cook C, Kaplow J, Bullock M, Schuster D.

    Ethn Dis. 2005 Autumn;15(4):641-8.PMID: 16259488 [PubMed - indexed for MEDLINE]Related articles

    18.

    The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

    Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS.

    Metabolism. 2005 Mar;54(3):314-20.PMID: 15736108 [PubMed - indexed for MEDLINE]Related articles

    19.

    Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

    Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W.

    Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):283-8.PMID: 12588772 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.

    Gee MK, Zhang L, Rankin SE, Collins JN, Kauffman RF, Wagner JD.

    Metabolism. 2004 Sep;53(9):1121-5.PMID: 15334371 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity